ANRS CO21 Cohort FRESH-PEF73422-en Faroudy BOUFASSA ANRS CO21 Cohort CODEX FRESH-PEF73422-en 73422 FRESH-PEF73422 Faroudy BOUFASSA AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) Epidemiology France Portal (PEF) AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) null Olivier;LAMBOTTE HIV Controllers HIV infection Infectious disease medicine Human immunodeficiency virus disease without mention of tuberculosis or malaria Biological determinants: Genetic predisposition Behavioral determinants Socio-demographic and economic determinants Biological determinants In HIV-1 positive patients who have been asymptomatic for at least 5 years after HIV infection in the absence of antiretroviral therapy, whether they meet the definitions of Long time non-Progressors and/or HIV Controllers and in patients on antiretroviral therapy and in "control after discontinuation of antiretroviral therapy", study their clinical and immuno-virological course and define the virus and host parameters associated with non-progression of infection. null France Individuals Patients population Male Female Other Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) LTNP subjects: Long Term Non Progressors: HIV-1 positive subjects for at least 8 years with a CD4+ lymphocyte count greater than 600/mm3 and stable or increasing (positive or zero slope) on at least 3 consecutive tests performed in the last 5 years regardless of viral load in the absence of antiretroviral treatment. HIC (HIV Controllers)" subjects: HIV-1 positive subjects for at least 5 years, asymptomatic, with the last 5 consecutive plasma HIV RNA viral loads < 400 copies/mL whatever the CD4+ level in the absence of antiretroviral treatment. LTNP-HIC" subjects: subjects meeting the double definition of LTNP and HIC, i.e. HIV-1 subjects who have been HIV-positive for at least 8 years and CD4+ lymphocyte count greater than 600/mm3 with a stable or increasing level (positive or zero slope) on at least 3 consecutive examinations carried out over the last 5 years and with the last 5 consecutive plasma HIV-RNA viral loads < 400 copies/mL. Subjects in "post-treatment control" (or post-treatment controllers, PTC): Subjects who had a plasma HIV-RNA viral load > 2000 copies/mL prior to initiation of antiretroviral therapy in either primary or chronic phase and who were maintained on antiretroviral therapy for at least 12 months; in whom, after antiretroviral therapy was discontinued, the viral load remained < 400 copies/mL for more than 12 months with the exception of one blip (plasma viral load above 400 copies/mL) surrounded by two viral loads < 400 copies/mL. The last plasma viral load at the time of inclusion should, in all cases, be < 400 copies/mL. Clinical data Biological data Health event/morbidity Health event/mortality Quality of life/health perception Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Converting or copying information into a structured record Interview with the participant (including clinical) Observational Study Observational Study Cohort study 346 Unknown Restricted access Availability of data after validation of a research project by the Scientific Council of the cohort. Data format on tables (SAS, Excel, Stata). Access on specific project only